YPL 001

Drug Profile

YPL 001

Alternative Names: YPL001

Latest Information Update: 11 Aug 2015

Price : $50

At a glance

  • Originator Yungjin Pharm Co
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Mar 2015 Phase-II clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA (PO) (NCT02272634)
  • 30 Oct 2014 Phase-I clinical trials in Chronic obstructive pulmonary disease in USA (PO)
  • 30 Oct 2014 Yungjin Pharm plans a phase II trial for Chronic obstructive pulmonary disease in USA (NCT02272634)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top